Flagship Biosciences Applauded by Frost & Sullivan for Changing Biomarker Analysis to Find Biomarkers that Aid Drug Development and Diagnostics
SAN ANTONIO, Feb. 15, 2023 /PRNewswire/ -- Frost & Sullivan assessed the artificial intelligence (AI)-enabled digital pathology solutions industry, and based on its findings, recognizes Flagship Biosciences with the 2023 North American Customer Value Leadership Award. The company is a technology-driven spatial biology and biomarker analytics service provider using the most precise and comprehensive data. The company's consultative approach and cutting-edge AI are changing biomarker analysis to enhance drug development and diagnostics. It uniquely leverages its technology to meet its customers' needs.
- The company is a technology-driven spatial biology and biomarker analytics service provider using the most precise and comprehensive data.
- The company's consultative approach and cutting-edge AI are changing biomarker analysis to enhance drug development and diagnostics.
- Flagship's solution goes beyond its extensive expertise and best-in-class technical capabilities, with customer value as a strategic imperative.
- Its customer-first approach offers immense value to existing and new customers," added Surbhi Gupta, an Industry Analyst at Frost & Sullivan.